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Current experimental and clinical knowledge supports the optimisation of endothelial cell targeting using a strategy combining anti-
EGFR drugs with antivascular agents. The purpose of the present study was to examine the effects of the association of ZD6126, an
antivascular microtubule-destabilising agent, with gefitinib and irradiation on the growth of six head and neck human cancer cell lines
xenografted in nude mice and to study predictive and molecular factors responsible for antitumour effects. CAL33- and Hep-2-
grafted cell lines were the most sensitive to ZD6126 treatment, with VEGF levels significantly higher (P¼0.0336) in these tumour
xenografts compared to Detroit 562- and CAL27-grafted cell lines with relatively low VEGF levels that were not sensitive to ZD6126.
In contrast, neither IL8 levels nor EGFR expression was linked to the antitumour effects of ZD6126. ZD6126 in combination with
gefitinib resulted in a synergistic cytotoxic interaction with greater antitumour effects than gefitinib alone. The synergistic interaction
between ZD6126 and gefitinib was corroborated by a significant decrease in CD31 labelling. The present study may serve for future
innovative clinical applications, as it suggests that VEGF tumour levels are possible predictors for ZD6126 antitumour efficacy. It also
supports the notion of antitumour supra-additivity when combining gefitinib and ZD6126, and identifies neoangiogenesis as the main
determinant of this synergistic combination.
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Tumour expression of growth factor receptors of the HER family
makes it possible to perform innovative therapeutic targeting as
demonstrated by the development of clinically active drugs such as
herceptin(
s), cetuximab and EGFR tyrosine kinase inhibitors
(Gross et al, 2004). The antiproliferative and antitumour effects of
these compounds are attributed to cellular physiological con-
sequences following receptor targeting manifested by inhibition of
cell proliferation, increased apoptosis and reduced tumour
neoangiogenesis (Woodburn, 1999). This ability to reduce tumour
neoangiogenesis by EGFR targeting has been attributed to the
inhibition of proangiogenic tumour factors such as VEGF and FGF
(Perrotte et al, 1999; Ciardiello et al, 2001). An interesting recent
study points out that EGFR targeting of tumours can also include
the endothelial cell network (Hirata et al, 2002). Endothelial cells
express EGFR. Thus, part of the global antiangiogenic effect
resulting from EGFR targeting can also be attributed to the direct
impact of EGFR-targeting agents on endothelial cells. Conse-
quently, a variable part of the antiangiogenic activity of EGFR-
targeting drugs could be caused by a dual effect: inhibition of
proangiogenic factors such as VEGF produced by the tumour itself
and a direct effect on the intra-tumour endothelial cells. It would
be interesting therefore to optimise endothelial cell targeting using
a strategy combining anti-EGFR treatment and an antivascular
approach. The vascular-targeting compound ZD6126 destabilises
microtubules and selectively disrupts immature tumour endothe-
lial cells, which stops tumour blood flow and induces tumour cell
death (Thorpe et al, 2003). A recent phase I study with ZD6126
underlines the potential impact of this compound on the
vasculature (Beerepoot et al, 2006). Associating ZD6126 with the
EGFR tyrosine kinase inhibitor gefitinib would thus combine an
antivascular agent and an anti-EGFR drug. Furthermore, as
ZD6126 is a compound acting on microtubules, it cannot be
excluded that part of its antitumour activity may also consist of
direct effects on tumour cells. Combining ZD6126 and gefitinib
would thus provide a potentially beneficial association of two
drugs producing optimal effects on both endothelial and tumour
cells. Recent preclinical studies suggest that radiotherapy in
combination with antiangiogenic/vasculature-targeting agents
may enhance the therapeutic ratio of ionising radiation alone
(Wachsberger et al, 2005). Thus, the association of ZD6126 and
gefitinib with irradiation could also be an interesting area for
investigation.
Tumour vasculature is a key target in the treatment of solid
tumours, particularly of the head and neck (Le and Giaccia, 2003).
In the present study, a panel of six different head and neck human
cancer cell lines was examined in a xenograft mouse model. These
tumour xenografts, in athymic nude mice, were studied for
predictive and molecular factors responsible for antitumour
effects.
MATERIALS AND METHODS
Chemicals
Gefitinib and ZD6126 were kindly provided by AstraZeneca
(Macclesfield, United Kingdom). Working solutions were prepared
extemporaneously as follows: gefitinib was suspended in 0.9%
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sNaCl, 0.01% Tween-80 and ZD6126 in 0.9% NaCl with pH adjusted
to 4.5. For both drugs, the concentrations were adjusted so as to
include the daily dose in 0.2ml of drug suspension. Dulbecco’s
modified Eagle’s medium (DMEM), penicillin, streptomycin and
glutamine were purchased from Whittaker (Verviers, Belgium).
Foetal bovine serum (FBS) was obtained from Dutscher (Brumath,
France).
Cell lines
Six different human head and neck cancer cell lines: CAL27,
CAL33, CAL60 and CAL166 originated from our institution (the
Centre Antoine Lacassagne); Detroit 562 and Hep-2 were obtained
from the American Type Culture Collection (Rockville, MD, USA).
These cell lines exhibit variable EGFR levels (ligand-binding assay;
Dassonville et al, 1993), doubling time, in vitro sensitivities to
gefitinib or RT and p53 status, as summarised in Table 1.
The cell lines were maintained as monolayer cultures in DMEM
supplemented with 10% FBS (vv
 1), 2mM glutamic acid,
50000Ul
 1 penicillin and 80mM streptomycin in a humidified
incubator (Sanyo, Japan) at 371C in an atmosphere containing 8%
CO2. Batches of 15 10
6 cells were frozen in FBS supplemented
with 5% DMSO (vv
 1) in advance for injection into mice. Shortly
before injection, cells were thawed and suspended in Ringer
lactate.
Mice
Animal experiments were performed in accordance with the
regulations of the institutional ethical commission and of the
United Kingdom Co-ordinating Committee on Cancer Research
guidelines (Workman et al, 1998). Six-week-old female Swiss nude
mice were purchased from Charles River (L’Arbresle, France) and
received subcutaneous inoculation in the right flank of 2 10
6 cells
dissolved in 100ml of Ringer lactate (six to eight animals per
treatment condition).
Tumours
Tumour length and width were measured weekly using a caliper.
Tumour volume was calculated as p/6 length width
2 until
animal killing. At that time, animals were killed by spinal cord
dislocation and tumours were subsequently removed surgically
and weighed; half of the tumour was directly frozen in liquid
nitrogen for protein analysis and the other half fixed in para-
formaldehyde overnight for CD31 and Ki67 examination using
microtissue array (MTA immunochemistry).
Preparation of samples for analysis of cellular factors
Frozen tumours were pulverised in a liquid nitrogen-cooled
Thermovac pulveriser. The resulting powders were homogenised
in 10 volumes of a 10mM Tris-HCl buffer (pH 7.4), containing
1m M EDTA, 0.5mM dithiothreitol and 10mM sodium molybdate.
The homogenates were centrifuged for 1h at 105000g (þ41C) and
the supernatants (cytosols) were used for protein determination by
immunoblotting. Total protein content was measured using the
bicinchoninic acid assay.
VEGF and IL8 were determined by ELISA using DVE 00 and
D8050, respectively, from Quantikine (Minneapolis, USA); EGFR
was determined by the
125I-EGF binding method followed by
Scatchard-plot analysis. These factors were chosen because VEGF
is the main growth factor for endothelial cells; IL8 is a
proangiogenic factor (as VEGF, bFGF and aFGF) with a proven
role in different tumour types and EGFR as it is the target of
gefitinib.
The microvessel marker CD31 (DAKO monoclonal antibody M/
B1 ref.: M7240) and the proliferation marker Ki67 (DAKO
monoclonal antibody JC70A ref.: M0823) were determined by
MTA on treated tumours obtained after animal killing.
Treatment
In vivo growth characteristics of the human head and neck cancer
xenografts Tumour volume was monitored once a week between
3 and 8 weeks depending on the cell line; the experiments were
stopped when tumours reached 1cm
3. The differential expression
of molecular factors potentially related to ZD6126 sensitivity such
as VEGF, IL8 (by ELISA) and EGFR (by ligand-binding assay) was
measured, at the end of the observation period, in untreated
tumours (tumour volume between 72 and 2344mm
3) after animal
killing.
Sensitivity of the six cell lines to ZD6126 Treatment was applied
when tumours reached a mean volume of 250mm
3; animals were
treated once a week for 3 weeks, with freshly prepared ZD6126
(200mgkg
 1) (Goto et al, 2004), or vehicle only (controls), and the
tumour volume monitored for 2 weeks after the end of treatment
period or until the mean volume of the controls reached 1cm
3.
Mice injected with CAL166 and CAL33 tumours, which grow
relatively quickly, could only be treated twice whereas all other
mice models were treated three times.
Effects of a single drug and their combination with irradiation on
tumour growth, tumour vessel density and molecular factors
representative of proliferation The effects of each single drug
and their combination with or without irradiation (RT) were
examined for the impact on tumour growth and tumour
angiogenesis (CD31) and on molecular factors indicative of
proliferation (Ki67). CD31 and Ki67 expressions were determined
in MTAs by immunohistochemistry (Simon et al, 2004) on CAL33,
a highly proliferative and moderately responsive cell line. The final
score was the result of the examination of three fields per tumour,
and between four and eight tumours were investigated. Labelling
intensities were scored as 0¼no, 1¼slight, 2¼medium,
3¼strong and 4¼very strong. Scoring was performed at the
end of the treatment sequence, on day 15, and at the end of
Table 1 Characteristics of head and neck cancer cell lines (historical data from in vitro experiments Magne ´ et al, 2002)
Cell line Origin EGFR level (fmolmg
 1 protein) p53 status Doubling time (h) IC50 radiation (Gy) IC50 gefitinib (lM)
CAL27 CAL 8258 (311) Mutant (exon 6) 18.2 (1.5) 6.2 (1.1) 17.5 (2.4)
CAL33 CAL 33794 (624) Mutant (exon 5) 17.5 (0.1) 2.6 (0.4) 6.07 (0.8)
CAL60 CAL 2703 (101) Mutant (exon 7) 11.8 (0.2) 5.1 (0.1) 11.4 (0.9)
CAL166 CAL 3253 (126) Wild type 13.1 (1.0) 6.2 (0.8) 22.8 (4.8)
Hep-2 ATCC 388 (27) Wild type 10.9 (1.0) 9.8 (0.3) 31.1 (2.4)
Detroit562 ATCC 668 (45) Mutant (exon 5) 14.8 (0.4) 7.7 (0.1) 20.6 (1.5)
ATCC¼American Type Culture Collection, Rockville; CAL¼Centre Antoine Lacassagne; EGFR¼epidermal growth factor receptor. Mean values (standard deviation) for
EGFR levels, doubling time and IC50 values. At least two separate experiments were performed to evaluate the EGFR content, and three individual experiments for the other
determinations.
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sexperiments on day 33. Time of termination of experiments was
dictated by ethical reasons (tumour volume in controls).
Mice bearing well-established CAL33 tumours (mean tumour
volume/treatment group B250mm
3) were treated every week with
vehicle alone (controls), ZD6126 (150mgkg
 1, 0.2ml intraperito-
neally on days 0, 7 and 14), gefitinib (120mgkg
 1day
 1,5
daysweek
 1 during 2 weeks, 0.2mlos
 1) and RT (3Gyday
 1,3
daysweek
 1 during 2 weeks). The dose of gefitinib was chosen
according to previous data in tumour xenografts in mice
(Formento et al, 2005) and the dose of ZD6126 was diminished
when compared to the monotherapy study in order to allow the
interaction with other agents to be put into evidence.
Interaction between ZD6126 and gefitinib alone or in combina-
tion with RT (when given on the same day, ZD6126 was applied 2h
after RT) was evaluated for tumour growth inhibition. The
sequence between gefitinib and RT was already established by us
from tumour experiments with the two agents applied to the same
tumour cell line xenograft (Formento et al, 2005).
The effects of the treatments were evaluated as described
previously (Prewett et al, 2002). Evaluation of the tumour effect
consisted in measuring the mean tumour volume on different
given days for the different treatment groups: controls, treatment
a, treatment b and treatment aþb. Fractional tumour volume
(FTV) for each treatment group was calculated as the ratio between
the mean tumour volumes of treated and untreated tumours. This
was performed for treatment a (FTVa), for treatment b (FTVb) and
for treatment aþb (FTVaþb). The expected FTV for the ‘aþb’
combination was defined as FTVa (observed) FTVb (observed).
The ratio FTVaþb (expected)/FTVaþb (observed) was the
combination ratio (CR). If CR 41, there are supra-additive effects
and if CR o1 infra-additive ones. Strictly additive effects are
observed if CR¼1.
The effects on CD31 and Ki67 were evaluated using the non-
parametric analysis of variance (Kruskal–Wallis test). The
differences between cell lines for molecular factors (VEGF, IL8
and EGFR) were examined using the Mann–Whitney test.
RESULTS
Tumour characteristics
The fastest growing xenografts were CAL166 and CAL33 with a
tumour volume doubling time of 7 and 10 days, respectively,
followed by Detroit 562 (tumour volume doubling time of 15 days)
(Figure 1). The other cell lines (CAL60, Hep-2 and CAL27) grew
relatively more slowly under the conditions of the present study.
There was a marked variation in VEGF and IL8 levels between
the six xenograft models examined. The variability in EGFR
expression was smaller between the studied cell lines (Figure 2).
The tumour volume did not influence VEGF secretion (Figure 3);
tumours originating from the same cell line, whatever their
respective volumes, maintain very comparable VEGF levels. The
VEGF intra-tumour concentration could thus be considered to be
strictly cell line dependent.
Effects of single-agent ZD6126
ZD6126 on its own exhibited relatively modest tumour growth
inhibition. There were marked disparities in the antitumour
activity of ZD6126 between the different xenografts (Figure 4). Of
note, for Detroit and CAL27 tumour xenografts, treatment with
ZD6126 conferred a growth advantage. CAL33 was moderately
sensitive and Hep-2 was the most sensitive to ZD6126 treatment.
VEGF levels were significantly higher (P¼0.0336) in these tumour
xenografts as compared to Detroit 562 and CAL27 xenografts for
which ZD6126 increased the tumour growth (Figure 2). Neither
EGFR nor IL8 tumour levels were linked to the differential
sensitivity to ZD6126.
Effects of ZD6126 in combination with gefitinib and
radiation
Figure 5A shows that, although ZD6126 had no apparent effect on
CAL33 tumour growth, its combination with gefitinib resulted in a
greater antitumour effect than with gefitinib alone (CR¼1.47, 1.35
and 1.15 at 19, 26 and 33 days, respectively, after cell injection,
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Figure 1 Growth (log scale) of the different xenografted tumours in
athymic nude mice. Bars represent standard error of the mean.
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swith between five and eight mice per treatment group). The
addition of RT did not modify markedly the observed antitumour
effects resulting from the ZD6126þgefitinib combination with a
tendency in this case to infra-additive interaction (CR¼0.87, 0.85
and 0.64 at 19, 26 and 33 days, respectively, after cell injection)
(Figure 5B).
Molecular parameters
At the end of the experiment (day 33), CAL33 tumours were
analysed for CD31 and Ki67 staining. Single-drug treatments with
either gefitinib or ZD6126 had a modest effect on CD31 tumour
labelling as compared to controls without drug (Figure 6). CD31
tumour labelling reflected accurately the antitumour effect
resulting from the different combinations. Thus, the synergistic
interaction between ZD6126 and gefitinib was confirmed by a
significant decrease in CD31 labelling (Po0.01) (Figure 6). There
was a less intense impact on CD31 labelling, corroborating the
effects on tumour growth, when applying the triple combination
ZD6126þgefitinibþRT as compared to the two-drug association
(Figure 6). In contrast to what was observed with CD31 labelling,
there was no clear link between Ki67 labelling and drug effects
(Figure 6). Similar observations were made at the end of the
treatment (day 15), but the relative diminution in CD31 labelling
resulting from the ZD6126–gefitinib association was less marked
at this time than at the end of the experiment on day 33 (data not
shown).
DISCUSSION
Tumour neoangiogenesis is a complex process that involves
multiple and interrelated steps dependent on positive and negative
regulatory growth factors (Wray et al, 2004). Given its importance
in the development of tumour-associated neoangiogenesis (Fer-
rara, 2005), the VEGF pathway has received constant attention as a
target in antiangiogenesis strategies using various approaches
(Ferrara, 2004). Among these approaches, one of the most
rewarding approach so far at the clinical level is the use of the
monoclonal antibody bevacizumab, which acts directly by deplet-
ing VEGF levels in physiological fluids (Stern and Herrmann,
2005). Another complementary tumour antiangiogenic strategy
consists in developing agents that are able to act directly on the
function of established endothelial cells in the tumour (Thorpe
et al, 2003). Microtubule-destabilising agents belong to this
category, where their mechanism of action is focused on the
disruption of the endothelial cell cytoskeleton (Hsieh et al, 2005).
One of the drugs belonging to this therapeutic class is ZD6126, a
phosphate prodrug of N-acetyl colchinol which has been shown to
induce pronounced but reversible changes in immature endothe-
lial cell morphology and to have marked vascular effects and
antitumour activity in preclinical models (Davis et al, 2002).
Antiangiogenic and vascular disrupting therapies target, at
different levels, the expanding tumour endothelial cell network.
It was tempting, therefore, to combine these classes of drugs. Such
an approach was recently adopted by Siemann and Shi (2004). The
authors report that significant antitumour efficacy could be
achieved by associating the potent VEGF-R2 and EGFR inhibitor
ZD6474 with ZD6126. As endothelial cells express EGFR, some of
the global antiangiogenic effects resulting from the use of EGFR-
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stargeting drugs may also be attributed to the direct impact on
endothelial cells (Hirata et al, 2002). Using the same strategy,
associating different antiangiogenic approaches, the present study
combined the well-known anti-EGFR drug gefitinib with the
antivascular agent ZD6126. The study focused on human head and
neck cancer cell lines as neoangiogenesis plays a critical role in the
development and evolution of tumours arising from the upper
aero-digestive tract (Nakaya et al, 2005; Shang and Lir, 2005). Head
and neck cancer is also known to express high levels of EGFR with
a strong prognostic value, and the ‘drugable’ relevance of this
growth factor has been reported by others (Pomerantz and
Grandis, 2003, 2004) and us (Dassonville et al, 1993; Etienne
et al, 1999; Pivot et al, 2005).
There is evidence that ZD6126 is active in various preclinical
tumour models with variable antitumour efficacy (Blakey et al,
2002; Evelhoch et al, 2004; Skliarenko et al, 2006). One of the
objectives of the present investigation was to examine the existence
of predictive intra-tumour factors that may explain the observed
effects. Based on the study of a panel of six different human cancer
cell lines of head and neck origin, it was confirmed that treatment
with ZD6126 results in variable antitumour effects. Of note, from
the study by Skliarenko et al (2006), there were tumours for which
the application of ZD6126 resulted in greater tumour growth as
compared to controls. This phenomenon of tumour re-growth
corroborates the present observation of higher growth than in
controls for Detroit and CAL27 xenograft under treatment by
ZD6126. Antitumour efficacy was observed for CAL33 and Hep-2
cell lines. Interestingly, these two cell lines were those for which
established tumours in animals expressed the highest VEGF levels.
This result is not particularly surprising and could be explained, as
a proof of the concept, by the fact that tumours with a high
expression of VEGF may be more dependent on neoangiogenesis
and the most sensitive to an antivascular therapeutic approach
with ZD6126. Neither EGFR nor IL8 levels were associated with the
differences in antitumour effects of ZD6126. The study by
Skliarenko et al (2006) put into evidence that tumours with higher
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Figure 5 (A) Effects of ZD6126 and gefitinib or ZD6126þgefitinib on
CAL33 tumour xenografts (filled triangles and arrows indicate the time of
treatments). Bars represent standard error of the mean. (B) Effects of
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arrows indicate the time of treatments). Tumour growth curves of
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EGFR targeting combined with antiangiogenesis
A Bozec et al
726
British Journal of Cancer (2006) 95(6), 722–728 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sinitial interstitial fluid pressure showed enhanced cell survival
following treatment with ZD6126. Thus, intrinsic tumour angio-
genesis may be related to the antitumour efficacy of ZD6126. These
findings may be useful at the clinical level as there is a risk of a
tumour-promoting effect of ZD6126. Selection of appropriate
candidates for treatment seems mandatory and could be based on
intra-tumour expression of VEGF.
The second part of this study was designed in a way similar to
the work recently published by Raben et al (2004) who combined
ZD1839 (gefitinib) with ZD6126 and irradiation. The authors
reported that the triple association applied to the A549 human
non-small-cell lung cancer xenograft model induced the greatest
effects on tumour growth and angiogenesis. The conclusions of the
present study are somewhat different. First, it is interesting to note
that, when examining the gefitinib–ZD6126 association on the
CAL33 head and neck human cancer cell line xenograft, it appears
that although ZD6126 shows no apparent antitumour efficacy by
itself at the dose used in the combination experiment (150mg per
day), the final effects become supra-additive when combined with
gefitinib (Figure 5A). This observation was strengthened by the
analysis of the impact of treatment on tumour neoangiogenesis
(CD31 labelling). Gefitinib or ZD6126 by themselves had no effect
on CD31 tumour labelling compared to controls without drug. In
contrast, the combination of these two drugs markedly reduced the
intensity of CD31 labelling in the tumours (Figure 6). There was in
contrast no evidence for an explanation of the supra-additive
effects between the two drugs when examining the impact of
combined treatment on tumour intrinsic proliferation capacity
(Ki67 labelling). Thus, it seems that the beneficial antitumour
effect of associating gefitinib and ZD6126 is more related to the
targeting of endothelial cells than to a diminution of the intrinsic
tumour growth. The mechanistic explanation for this synergistic
effect on tumour angiogenesis may lie in the fact that each drug
has a distinctive impact on endothelial cells. ZD6126 directly
affects the internal structure of the endothelial cell, whereas
gefitinib acts through inhibition of EGFR signalling of endothelial
cells and by reduced production of proangiogenic factors by
tumour cells (Hirata et al, 2002). The potential direct impact of
ZD6126 on the vasculature has been underlined during a recent
phase I study with this compound (Beerepoot et al, 2006). Thus,
the multiple complementary impacts on endothelial cells may lead
to measurable effects on tumour growth, although the effect of
ZD6126 alone may not be macroscopically visible at this dose.
Previous experimental studies showed potential beneficial
antitumour effects when combining ZD6126 with RT (Siemann
and Rojiani, 2002; Raben et al, 2004). A recent study (Wachsberger
et al, 2005), however, drew more contrasting conclusions with data
suggesting that the optimal therapeutic benefit of ZD6126 plus RT
(U87 glioblastoma xenograft) is schedule-dependent with combi-
nations of ZD6126 before each dose of RT being less effective than
RT alone. The importance of the scheduling involving ZD6126 and
RT was also reported by a previous study (Siemann and Rojiani,
2002) that showed that this association increased tumour cell
killing of KHT mouse sarcoma when given 24h before RT or 1h or
more following RT, but was not found to be as effective if given 1h
before RT. In the present study, the sequence of association
between RT and ZD6126 was taken into consideration as the drug
was given 2h after RT. The impact of the association of RT with
drugs was examined with the triple combination and it was found,
in the present conditions, that RT did not markedly modify the
antitumour effect resulting from the ZD6126–gefitinib association
(Figure 5B). Of note, this observation was corroborated by
examining CD31 tumour labelling, which showed a less intense
impact on this parameter when applying the triple combination as
compared to the gefitinib–ZD6126 association.
Overall, the present study may contribute to future innovative
clinical applications and suggests that the VEGF tumour level is a
possible predictor for ZD6126 antitumour efficacy, that it
strengthens the notion of antitumour supra-additive effects when
combining gefitinib and ZD6126, identifies neoangiogenesis as the
main impact of this synergistic combination and gives no firm
support to the benefit of adding RT to the drug association.
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